January 11, 2018 / 1:18 PM / 8 months ago

BRIEF-Immunomedics Announces Agreement With University Of Wisconsin Carbone Cancer Center To Expand Sacituzumab Govitecan Into Prostate Cancer

Jan 11 (Reuters) - Immunomedics Inc:

* IMMUNOMEDICS ANNOUNCES AGREEMENT WITH UNIVERSITY OF WISCONSIN CARBONE CANCER CENTER TO EXPAND SACITUZUMAB GOVITECAN (IMMU-132) INTO PROSTATE CANCER

* IMMUNOMEDICS INC - ‍IMMUNOMEDICS TO FUND PHASE 2 STUDY SPONSORED BY UNIVERSITY OF WISCONSIN​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below